OOIR: Observatory of International Research

Papers

(The H4-Index of Liver International is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Issue Information	255
Methylprednisolone‐Induced Liver Injury: Insights From FAERS Analysis and Comparison With DILIN Findings	113
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals	106
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway	104
Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR‐MASH Score’	101
Association of Liver Disease and Chronic Pruritus: A Case–Control Study	91
Reply: Herbal‐Induced Liver Injury Identification and Prevention	86
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	80
The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability	78
Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis	77
Perilipin 5 protects the mitochondrial oxidative functions and improves the alcoholic liver injury in mice	77
Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	70
Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma	67
Response to Letter to the Editor: “Chronic Nanoplastic Exposure as a Novel Risk Amplifier for MASLD Progression”	65
Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs	62
TIPS Superiority in Refractory Variceal Haemorrhage: Insights From the TIPSEMS ‐ VB	62
Assessment of PBC Pruritus From the ITCH ‐E Study: Quality of Life, Productivity, and Treatment Ex	62
Causal effect of lower birthweight on non‐alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites	61
Benefits of Using cT1 for Risk Stratification in MASLD	60
On Evaluating GPT ‐4 for CHB Treatment Recommendations: Reproducibility, Vignette Design and Promp	58
Reply to “Probiotics for Hepatic Encephalopathy Prevention After TIPS : Still an Open Question”	58
Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population	55
Helicobacter pylori‐Associated Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut Barrier Damage in Liver Cirrhosis	53
Prognosis of hospitalized patients with cirrhosis and acute kidney disease	53
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	53

Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta‐analysis	53
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	49
Hospitalisations With Cryoglobulin‐Related Diseases in Spain Over 25 Years	48
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	46
HBV cure—The light at the end of the tunnel?	45
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	45
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	44
Inside Front Cover	42
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	41
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	41
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	41
Issue Cover	38
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis	38
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study	38
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	38